Table 2.

Duration of subcutaneous sirukumab/placebo treatment (safety population)

	Sirukumab 100 mg q2w + 6-month prednisone (n = 42)	Sirukumab 100 mg q2w + 3-month prednisone (n = 39)	Sirukumab 50 mg q4w + 6-month prednisone (n = 26)	6-Month prednisone (n = 27)	12-month prednisone (n = 27)
Duration of SC sirukumab/placebo treatment (weeks)a
Mean (SD)	25.8 (18.3)	27.1 (17.3)	29.6 (15.1)	29.5 (18.5)	30.2 (17.1)
Median (min, max)	24.0 (0.1, 50.3)	26.1 (0.1, 52.1)	26.3 (2.1, 50.3)	30.1 (0.1, 56.3)	30.0 (4.1, 51.9)

q2w every 2 weeks, q4w every 4 weeks, Max maximum, Min minimum, SC subcutaneous, SD standard deviation

^aDuration of SC sirukumab/placebo exposure was defined as (date of last SC sirukumab/placebo dose—date of first SC sirukumab/placebo dose + 1)/7